Relationship between loperamide-induced sedative effect and digoxin pharmacokinetics in healthy Japanese subjects
- PMID: 15835747
- DOI: 10.1007/s11095-004-1879-6
Relationship between loperamide-induced sedative effect and digoxin pharmacokinetics in healthy Japanese subjects
Abstract
Purpose: Loperamide-induced suppressive effects on central nervous system closely relate to a lack of or decline in the P-glycoprotein (P-gp) function. The aim of this study was to determine the loperamide-induced sedative effect quantitatively and to investigate possible alterations in the pharmacokinetics of digoxin, a substrate for P-gp, in Japanese subjects.
Methods: Loperamide hydrochloride (2 mg) was administered orally to 26 subjects and the critical flicker-fusion frequency threshold (CFF) values were measured every 30 min separately by portable instrument. Further, digoxin (0.25 mg) was administered to 8 subjects, and the plasma concentration was determined.
Results: In five subjects who complained of drowsiness, the CFF values more remarkably decreased compared with those in the other subjects. The Tmax and mean residence time (MRT) values of digoxin pharmacokinetics in four subjects with drowsiness were significantly lower and Cmax was higher than those in four subjects with marginal effect. Moreover, there were good correlations between the CFF value-time profile and the Cmax, Tmax, and MRT of digoxin.
Conclusions: The determination of the CFF value after oral administration of loperamide will be useful for evaluating varied P-gp function and for anticipating individual variations in the disposition of P-gp substrates in humans.
Similar articles
-
Sedative properties of doxepin in comparison with diazepam.Psychopharmacology (Berl). 1977 Oct 20;54(2):165-9. doi: 10.1007/BF00426774. Psychopharmacology (Berl). 1977. PMID: 412211
-
Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats.Arch Pharm Res. 2003 Sep;26(9):768-72. doi: 10.1007/BF02976689. Arch Pharm Res. 2003. PMID: 14560928
-
No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects.Clin Pharmacol Ther. 2003 Nov;74(5):487-98. doi: 10.1016/S0009-9236(03)00234-0. Clin Pharmacol Ther. 2003. PMID: 14586389 Clinical Trial.
-
Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein.Clin Pharmacol Ther. 2002 Aug;72(2):209-19. doi: 10.1067/mcp.2002.126177. Clin Pharmacol Ther. 2002. PMID: 12189368
-
Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers.Br J Clin Pharmacol. 2014 Sep;78(3):556-64. doi: 10.1111/bcp.12368. Br J Clin Pharmacol. 2014. PMID: 24602137 Free PMC article. Clinical Trial.
Cited by
-
Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.Clin Pharmacokinet. 2010 Apr;49(4):223-37. doi: 10.2165/11318000-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20214407 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous